Eribulin Effective In Metastatic Breast Cancer, According Study

Eribulin Effective In Metastatic Breast Cancer, According Study
shutterstock_84435181 (1)An international research team recently published results of the study "Eribulin, A Drug Originally Developed In Sea Sponges Can Increase Survival In Women With Triple Negative Breast Cancer" in the Journal of Clinical Oncology, whereby they demonstrate eribulin is a well-tolerated and active therapy for women suffering with metastatic breast cancer (MBC) as first, second or third line chemotherapy regimen. This is the first research study assessing eribulin in the early course of metastatic breast cancer. Lead researchers Dr. Peter Kaufman observed in a news release: “It is of great interest that subset analysis suggests that eribulin may be particularly active and effec
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.